Why the study?
Does dapagliflozin maintain consistent efficacy and safety across diuretic subgroups in patients with heart failure and reduced ejection fraction?
Does dapagliflozin maintain consistent efficacy and safety across diuretic subgroups in patients with heart failure and reduced ejection fraction?
Dapagliflozin demonstrates consistent efficacy and safety regardless of baseline diuretic use in patients with HFrEF.
Supports dapagliflozin use in HFrEF irrespective of diuretic background; confirms broad applicability of DAPA-HF results.
The efficacy and safety of dapagliflozin were consistent across the diuretic subgroups examined in DAPA-HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: